Takeda Pharmaceuticals Accused of Hiding Dangers of Actos

Actos is a Type 2 diabetes drug that was approved by the Food and Drug Administration (FDA) in 1999. The drug decreases insulin resistance and decreases glucose made in the liver. It also allows the body to dispose of excess blood sugar and makes the body’s cells more sensitive to insulin.

Actos Lawsuit Details

Actos lawsuits claim Takeda Pharmaceuticals, the drug’s manufacturer, and Eli Lilly, the drug’s marketer, knew about bladder cancer risks but did not warn the public. Eli Lilly partnered with Takeda Pharmaceuticals, the largest pharmaceutical company in Japan and Asia, to market the drug. After their partnership, Actos became one of the most successful diabetes drugs of all time. Sales in the United States reached $3.58 billion in 2010, and the sales made up 27 percent of Takeda’s revenue.

In 2011, the FDA required Takeda to update Actos’ warnings and precautions to include a warning that the drug may be associated with an increased risk of bladder cancer.

Takeda Executives Accused

More than 3,500 Actos suits have been consolidated before United States District Judge Rebecca Doherty in Lafayette, Louisiana. Lawyers claim Takeda executives knew in 2004 that studies found links between Actos and cancer but failed to issue a warning until seven years later to protect billions in sales of the drug.

Contact a Drug Injury Attorney Today

If you or a loved one have been injured as a result of a defective drug, contact the Indianapolis Drug Injury Attorneys of Wilson Kehoe Winingham. The lawyers at WKW can help you get the compensation you deserve. Call 317.920.6400 or fill out an online contact form for a free, no-obligation case evaluation.

Share This Article